Kenai Therapeutics (Kenai) is a biotechnology company pioneering next generation approaches to cure neurological disorders. The Company utilizes allogeneic induced pluripotent stem cell (iPSC) technology, a Nobel Prize-winning breakthrough that enables scientists to manufacture many human cell types, in order to advance Kenai's off-the-shelf neuron replacement therapeutics. By focusing on an iPSC technology platform, and forging partnerships with global leaders in surgical delivery and clinical development, Kenai is dedicated to advancing a best-in-class pipeline targeting neurological diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/29/24 | $82,000,000 | Series A |
Alaska Permanent Fund Cure Ventures Euclidean Capital Saisei Ventures The Column Group | undisclosed |
